Table 1

Patient characteristics at baseline*

Rituximab+ MTX
All Exposure (n=3194)
MTX >5 years (n=627)
Placebo+MTX (n=818)
Age (years)51.551.851.0
Female (%)80.880.180.4
Disease duration (years)8.311.17.1
Swollen joint count20.021.517.7
Tender joint count31.132.428.6
CRP (mg/dl)2.833.372.83
ESR (mm/h)
RF-positive (%)77.685.381.3
Number of previous biologicals or DMARDs†
Number of previous biologicals0.70.90.5
Baseline concomitant corticosteroids (%)52.455.053.2
  • *Baseline characteristics were the observed mean values of the original baseline, where original baseline was the screening or baseline visit in the patient's original study.

  • †Excluding MTX.

  • CRP, C reactive protein; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RF, rheumatoid factor.